Comprehensive Range of Research Tools from Abcam to Untangle Tau

Introduction

An extensive range of research tools are available from Abcam to comprehensively study tau pathology. From aggregation inhibitors to antibodies and kits, customers can obtain everything they need to unravel tau, in one place.

Figure 1. Formation of neurofibrillary tangles (NFTs) by the tau protein in tauopathies such as Alzheimer’s disease (AD). Under pathological conditions tau becomes hyperphosphorylated and detaches from microtubules. Phosphorylated tau then aggregates to form paired helical filaments (PHFs) and neurofibrillary tangles (NFTs).

Total tau detection

In the normal brain, tau exists in soluble form. However, it aggregates and becomes insoluble in AD. Total tau can be easily detected with a BS and azide-free antibody, an ELISA kit, or an antibody panel from the table given below.

Reagent

Recommended product

abID

Total tau antibody

Anti-Tau antibody [TAU-5] - BSA and Azide free

ab80579

Tau antibody panel

Tau Research Antibody Panel

ab226492

ELISA

Human Tau ELISA Kit

ab210972

Note: Studying insoluble tau can be problematic, consider using detergents such as RIPA and Sarkosy1.

Tau phosphorylation

Phosphorylation, which governs tau function, becomes dysregulated during pathology, ending in mislocalization, aggregation, and neuronal death. All aspects of tau phosphorylation can be effortlessly studied with antibodies against different post-translationally modified sites.

Phosphorylation site

Recommended product

abID

Serine 202 and threonine 205

Anti-Tau (phospho S202 + T205) antibody [EPR20390]

ab210703

Threonine 231

Anti-Tau (phospho T231) antibody [EPR2488]

ab151559

Serine 262

Anti-Tau (phospho S262) antibody

ab64193

Serine 396

Anti-Tau (phospho S396) antibody [EPR2731]

ab109390

Serine 422

Anti-Tau (phospho S422) antibody [EPR2866]

ab79415

Tau aggregation inhibitors

The presence of tau in aggregated form corresponds with pathology in diseases such as Alzheimer’s. The formation of neurofibrillary tangles can be effectively inhibited with a potent tau aggregation inhibitor.

Small molecule

Activity

abID

TRx0237 mesylate (LMTX)

Reduces tau pathology and reverses behavioral impairment in mice2. Active in vitro and in vivo3.

ab223882

AZD2858

Selective GSK-3 inhibitor (IC50 = 68 nM) of tau phosphorylation at the S396 site4.

ab223889

INDY

ATP-competitive Dyrk1A inhibitor capable of reversing tau phosphorylation5.

ab223890

GSK-3β Inhibitor VII

Cell-permeable, non-ATP competitive GSK-3β inhibitor (IC50 = 0.5 µM)6.

ab145937

YM-01 (YM-1)

Allosteric Hsp70 modulator which potently reduces aberrant tau levels (EC50 ~ 0.9 μM)7.

ab146423

Tau and neuroinflammation

In neurodegenerative disease, there is a complex interplay between misfolded proteins and neuroinflammation. Abcam offers a range of tools to investigate proinflammatory mediators, which allows researchers to study tau in the context of neuroinflammation.

Tool

Recommended product(s)

abID

Mouse and human multiplex cytokine panels

Human Key cytokines (15 plex) Multiplex Immunoassay Kit

ab213392

Mouse Key cytokines (14 plex) Multiplex Immunoassay Kit

ab213396

TNF alpha ELISA kit

Mouse TNF alpha ELISA Kit

ab208348

IL-1 beta ELISA kit

Mouse IL-1 beta ELISA Kit (Interleukin-1 beta)

ab100704

IL-6 ELISA kit

Human IL-6 ELISA Kit (Interleukin-6) High Sensitivity

ab46042

Customers can profile multiple cytokines with a pre-designed panel, or they can define their own. Abcam offers a range of SimpleStep ELISA® kits, using which one can obtain results within 90 minutes.

  1. Forest, S. K., Acker, C. M., d’Abramo, C. & Davies, P. Methods for measuring tau pathology in transgenic mouse models. J. Alzheimers. Dis. 33, 463–71 (2013).
  2. Melis, V. et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav. Pharmacol. 26, 353–368 (2015).
  3. Panza, F. et al. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy? Expert Opin. Pharmacother. 17, 457–461 (2016).
  4. Marsell, R. et al. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone 50, 619–627 (2012).
  5. Ogawa, Y. et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat. Commun. 1, 1–9 (2010).
  6. Conde, S. et al. Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching. (2003). J Med Chem. 46, 4631-3 (2003).
  7. Abisambra, J. et al. Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol. Psychiatry 74, 367–374 (2013).

About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 5, 2018 at 5:04 AM

Other White Papers by this Supplier